{"transactions":[{"id":4354,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10026,"kind":"person","name":"Mills Roger","position":1,"cik":"0001368190","reported_name":"Mills Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:05:24.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":50000,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105496","document":"tm2624769-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105496/tm2624769-7_4seq1.xml","form_type":"4"}},{"id":4353,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10026,"kind":"person","name":"Mills Roger","position":1,"cik":"0001368190","reported_name":"Mills Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:05:24.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105496","document":"tm2624769-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105496/tm2624769-7_4seq1.xml","form_type":"4"}},{"id":4352,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10026,"kind":"person","name":"Mills Roger","position":1,"cik":"0001368190","reported_name":"Mills Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-04T20:05:24.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":392837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026"}],"balance_after":785976,"source":{"system":"sec-edgar","filing":"0001104659-26-105496","document":"tm2624769-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105496/tm2624769-7_4seq1.xml","form_type":"4"}},{"id":4351,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10026,"kind":"person","name":"Mills Roger","position":1,"cik":"0001368190","reported_name":"Mills Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2026-09-04T20:05:24.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":392837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 392,837 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 342,837 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 50,000 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026"}],"balance_after":393139,"source":{"system":"sec-edgar","filing":"0001104659-26-105496","document":"tm2624769-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105496/tm2624769-7_4seq1.xml","form_type":"4"}}]}